''Important Footnote: Since Pluristem has 71 patents pending one can easily surmise that I have only touched upon a small portion of the indications that Pluristem has filed for patent protection. It is my belief that their potential treatable indications now number in the 40-60 range! If one reviews Dr. William Prather's webcast from the ONEMEDPLACE Conference from July 17th,2012 in New York City, you will see/hear that they have the ability to change the cellular growth environment within their 3-D Bioreactor in order to treat many different indications. Something no other company is able to do from a 2-D cell expansion process. Hence the 71 pending patents. Here is the website for that presentation by Dr. Parther:''

http://www.onemedplace.com/database/list...